Handelsavisen
prelaunch
Companies ›Healthcare ›1952.HK
19
1952.HK — HKEX Pharmaceuticals

Everest Medicines Ltd

HK$31,66
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-36,0 %
ROE
-5,6 %
Net margin
-17,4 %
Debt / equity
0,17
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Everest Medicines Ltd is a biopharmaceutical company focused on the development and commercialization of innovative therapies in China, primarily in the areas of oncology, autoimmune diseases, and rare diseases.

Business. Everest Medicines Ltd (1952.HK) is a pharmaceutical company engaged in the research, development, and commercialization of medicines. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY7 analysts
4 buy3 hold0 sell
Avg 12m price target54,40

Analyst recommendations

7 analysts · consensus Buy
Buy4
Hold3
Sell0
12-month price target
54,40
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
7 analysts · indicative
Ownership
—
not yet wired
Profitability→
-5,6 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1952.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1952.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Everest Medicines Ltd (1952.HK) is a pharmaceutical company engaged in the research, development, and commercialization of medicines. The firm operates within the Healthcare sector, specifically focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not provided in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Everest Medicines operates with a capital structure that includes a debt-to-equity ratio of 0.17, indicating a relatively low leverage position. The company's liquidity position is characterized by a current ratio of 4.89, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of -92.56 million CNY and free cash flow of -489.59 million CNY, indicating cash outflows from operations.

    In terms of profitability, Everest Medicines reported a net loss of 297.77 million CNY and an operating loss of 613.96 million CNY for the period. The return on equity (ROE) was -5.61%, and the return on assets (ROA) was -4.36%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not currently generating returns that meet industry expectations.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification provided in the available data, indicating that the company's revenue is primarily derived from operations within China. This concentration may expose the company to regional economic and regulatory risks.

    Everest Medicines reported revenue of 1.71 billion CNY for the period. While the company is in a growth phase, the financial data does not provide a clear trajectory for future revenue growth. The company's capital expenditures amounted to 348.34 million CNY, indicating ongoing investment in infrastructure and operations.

    The risk assessment for Everest Medicines indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to fund operations without external financing. The company has not disclosed any recent dilutive events, and the dilution risk remains low based on the current capital structure.

    There are no recent events or filings disclosed in the available data that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any material changes in its business strategy or operations in the most recent reporting period.

    Key takeaways
    • Everest Medicines has a strong liquidity position with a current ratio of 4.89 but is experiencing negative operating and free cash flows.
    • The company is not currently generating returns that meet industry standards, with ROE and ROA both in negative territory.
    • Revenue is concentrated in a single business segment and geographic region, exposing the company to regional risks.
    • The company is investing in capital expenditures, indicating ongoing development and expansion efforts.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk, with no recent dilutive events disclosed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$31,66
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    HK$5.30B
    Net cashⓘ
    -HK$198.8M
    Current ratioⓘ
    4.9
    Debt / equityⓘ
    0.2
    ROAⓘ
    -4.4%
    ROEⓘ
    -5.6%
    Cash conversionⓘ
    31.0%
    CapEx / revenueⓘ
    -20.4%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,85
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    7
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-20 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,85
    Revenue—no estimate—no estimate3,3B CNY
    Operating income—no estimate—no estimate250,1M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution7 analysts
    Strong buy2
    Buy2
    Hold3
    Sell0
    Strong sell0
    12-month price targetHK$54,40 · Median HK$48,30
    Low HK$40,70High HK$84,00
    Operating income · consensus250,1M CNY
    EPS surprise
    −34,1 %
    reported vs consensus · miss
    Revenue surprise
    −48,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$40,70
    MeanHK$54,40
    MedianHK$48,30
    HighHK$84,00
    SpotHK$31,66
    +71.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-36,0 %Bottom quartile
    Net Margin-17,4 %Bottom quartile
    ROE-5,6 %Below median
    Capex / Rev-20,4 %Bottom quartile
    D/E0,17Below median
    Cash Conv0,31Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Everest Medicines Ltd Market data — financials · 2026-05-26
    • Everest Medicines Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Leadership

    • Yongqing LuoChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1952.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage